👤 Hellen Carolliny de Souza Nicolau

Lipid Nanoparticles (LDE) have been used as a drug delivery vehicle to treat various diseases. LDEs resemble the structure of human low-density lipoprotein (LDL), but lack apoliprotein B (apo-B). The aim of this study was to determine whether changes in the proportion of unesterified cholesterol (UC) or triacylglycerols (TG) affect the physical stability of LDE in aqueous solutions over a six-month observation period, as analysed by Ultra Small-angle X-ray Scattering (USAXS), Dynamic Light Scattering (DLS) and zeta potential measurements. It was shown that variations in UC or TG content in the initial lipid mixture did not alter the size of the resulting LDE nanoparticles, which remained within the 30-35 nm range. This particle size was maintained for up to three months in formulations with varying TG content and up to four months in those with varying UC content. Thereafter, a progressive increase in nanoparticle size was observed, which suggests enhanced aggregate formation and reduced of LDE stability between 3 and 6 months of storage. This loss of stability did not appear to be directly related to changes in UC or TG composition. Notably, USAXS and DLS measurements yielded comparable results, which reinforces the reliability of the data. In addition, the zeta potential remained close to zero for all seven nanoparticle compositions throughout the six months, indicating that all LDE formulations had electrostatic neutral potential and remain so when they progressively aggregate with time. Complementary analyses also showed that LDE particles are, on average, spherical in shape. Overall, these findings provide relevant insights for the rational design of lipid mixtures in the preparation of nanoemulsions for drug delivery applications. Show less

Glioblastoma (GBM) is an aggressive and highly heterogeneous tumor that frequently recurs despite surgery followed by radio-chemotherapy and, more recently, TTFields. This recurrence is largely driven by glioblastoma stem cells (GSCs), which are intrinsically resistant to standard therapies. Identifying molecular targets that underlie this resistance is therefore critical. Here, we investigated whether the inhibition of FGFR1, previously identified as a key mediator of GBM radioresistance, using pemigatinib, a selective FGFR1-3 inhibitor, could enhance GSC radiosensitivity in vitro and in vivo. Pemigatinib treatment inhibited FGFR1 signaling, promoted proteasome-dependent FGFR1 degradation, and reduced the viability, neurosphere formation, and sphere size in GSCs with unmethylated MGMT, a subgroup known for poor response to standard treatments. In MGMT-unmethylated differentiated GBM cell lines, pemigatinib combined with temozolomide further enhanced radiosensitivity. Transcriptomic analysis revealed that pemigatinib treatment led to the downregulation of Show less

The study evaluated the association of Case-control study. Brazilian Oral Cleft Group. The study included 881 healthy controls and 800 patients with different types of NSOC: 232 with cleft lip only (NSCLO), 568 with cleft lip and palate (NSCLP), and 274 with cleft palate only (NSCPO). The genomic DNA was genotyped with allelic discrimination assays for five Although only nominal Our results demonstrate an increased risk of NSCL  ±  P in Brazilian individuals with enrichment of African ancestry in the presence of the Show less

Single exon duplications account for disease in a minority of Duchenne muscular dystrophy patients. Exon skipping in these patients has the potential to be highly therapeutic through restoration of full-length dystrophin expression. We conducted a 48-week open label study of casimersen and golodirsen in 3 subjects with an exon 45 or 53 duplication. Two subjects (aged 18 and 23 years) were non-ambulatory at baseline. Upper limb, pulmonary, and cardiac function appeared stable in the 2 subjects in whom they could be evaluated. Dystrophin expression increased from 0.94 % ±0.59% (mean±SD) of normal to 5.1% ±2.9% by western blot. Percent dystrophin positive fibers also rose from 14% ±17% at baseline to 50% ±42% . Our results provide initial evidence that the use of exon-skipping drugs may increase dystrophin levels in patients with single-exon duplications. Show less

Patients with coronary artery disease (CAD) and previous ischemic cerebrovascular events (ICVE, ischemic stroke, or transitory ischemic attack) constitute a high-risk subgroup for cardiovascular outcomes. High-density lipoprotein cholesterol (HDL-C) levels are correlated with cardiovascular events. Lipid transfer to HDL affects structure size and HDL subclass profile. Impairment of this transfer could influence ischemic risk seen in patients with CAD + ICVE. The objective was to evaluate the HDL ability to receive the lipids in patients with CAD with or without ICVE. Patients with CAD + ICVE (n = 60) and patients with CAD only (n = 60) were matched by age, sex, acute coronary syndromes (ACS) event type, and time elapsed between the ACS event and inclusion in the study. Lipid transfer to HDL was evaluated by incubating donor lipid nanoparticles labeled with radioactive unesterified cholesterol (UC) and esterified cholesterol (EC), phospholipid (PL), and triglyceride (TG) with whole plasma. After the chemical precipitation of non-HDL fractions and nanoparticles, the supernatant was counted for HDL radioactivity. CAD + ICVE group presented with impaired lipid transfer to HDL for PL (CAD + ICVE: 21.14 ± 2.7% vs CAD: 21.67 ± 3.1%, P = .03), TG (CAD + ICVE: 4.88 ± 0.97% vs CAD: 5.63 ± 0.92%, P = .002), and UC (CAD + ICVE: 5.55 ± 1.19% vs CAD: 6.16 ± 1.14%, P = .009). Lipid transfer to HDL was similar in both groups for EC. Adjusted models showed similar results. Patients with CAD and ICVE have reduced lipid transfer to HDL compared to those with CAD only. Dysfunctional HDL may account for the higher incidence of ischemic outcomes observed in this population. Show less